July 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Heba Youssef: When to Start Anticoagulation Therapy After Intracerebral Hemorrhage

Heba Youssef/LinkedIn

May 20, 2026, 11:41

Heba Youssef: When to Start Anticoagulation Therapy After Intracerebral Hemorrhage

Heba Youssef, Clinical Nutrition pharmacist at Helwan General Hospital, shared a post on LinkedIn:

“Timing Anticoagulation After Intracerebral Hemorrhage – One of the Hardest Calls in ICU

Few decisions in neurocritical care demand as much clinical judgment as this one:

When – if ever – do we restart anticoagulation after an intracranial hemorrhage?

Start too early – risk of catastrophic rebleeding.

Wait too long – life-threatening thromboembolism.

There is no universal answer.

But there is a framework.

The guiding principle: Individualization over protocol

Anticoagulation is almost always delayed after ICH – but the exact timing must be tailored to each patient’s unique risk profile, weighing hemorrhagic risk against thromboembolic risk with precision.

Before any restart is even considered

A structured pre-restart checklist should be non-negotiable:

Hematoma stability confirmed on repeat CT.
No evidence of active or ongoing bleeding.
Blood pressure rigorously controlled.
Neurological status stable.

Factors that shape the decision

Favoring earlier restart:

Mechanical heart valves.
Recent massive PE.
High-risk DVT.

Favoring delayed restart:

Large lobar hemorrhage
Cerebral amyloid angiopathy (CAA)
Uncontrolled hypertension.
Elderly patients with multiple comorbidities.

Suggested timelines – a framework, not a formula

Indication , Suggested Window

DVT Prophylaxis – 24–48 hrs post stable CT
High-Risk Thrombosis (e.g., mechanical valves) – approximately 7–14 days (specialist-guided)
Atrial Fibrillation (moderate risk) – 4–8 weeks

These windows are informed by the AHA/ASA 2022 ICH Guidelines, ESO Guidelines, and Neurocritical Care Society recommendations — but every case requires multidisciplinary input and serial reassessment.

This is not a decision made once.

It requires:

Repeat imaging
Multidisciplinary team collaboration
Ongoing risk-benefit reassessment

I’ve developed a comprehensive infographic summarizing these principles as a practical decision-support tool for clinicians navigating this challenge at the bedside.

Save it. Share it with your team.

And I’d love to hear how your institution approaches this – drop your protocol or experience in the comments.”

Heba Youssef: When to Start Anticoagulation Therapy After Intracerebral Hemorrhage